Skip to content

European market access and clinical adoption

Quint Healthcare helps international medical technology and digital health companies understand how a product can enter, be purchased and become routine practice in Germany and selected European markets.

Regulatory clearance is necessary, but it does not define the buyer, reimbursement route, workflow change or clinical evidence that drives adoption. These questions must be answered for the specific technology, indication and care setting.

Why this matters now

Europe's medtech opportunity is substantial, but the route to scale remains fragmented by country, care setting, reimbursement and procurement. The European Commission's startup and scaleup strategy identifies fragmentation and market uptake as persistent barriers to turning technology into European growth.

Health systems are also under workforce pressure. The OECD and European Commission estimated an EU shortage of around 1.2 million doctors, nurses and midwives in 2022 and identify digital technologies and AI as potential means of augmenting productivity. For manufacturers, this changes the adoption question: a product must show how it improves or redistributes work, not merely that clinicians find the technology interesting.

When this service is useful

  • A product has traction in another country but limited progress in Germany.
  • Clinicians are interested, yet the purchasing pathway remains unclear.
  • The team is uncertain whether DiGA, hospital procurement, private payment, selective contracts or another route is relevant.
  • Several indications are possible and the first market segment has not been selected.
  • Pilot sites exist, but use does not spread beyond individual champions.
  • Installed devices are used inconsistently and the cause is unclear.
  • A company needs reference sites, clinical users or an advisory structure without turning scientific exchange into promotion.

Market access starts with the real decision pathway

The first task is to map:

  • the clinical problem and current standard of care;
  • the intended user and patient population;
  • who benefits, who pays and who is accountable;
  • how purchasing and reimbursement decisions are made;
  • what evidence each stakeholder expects;
  • which part of the clinical workflow must change;
  • what a credible first market segment and reference site look like.

Germany is a particularly important and complex healthcare market. A DiGA pathway assessment, where relevant, must begin with the product's intended purpose, regulatory status, evidence and use context rather than with the attractiveness of the reimbursement label.

What we do

Market and stakeholder assessment

We analyse market structure, customer segments, reimbursement logic, clinical stakeholders, competitors and realistic points of entry. Desk research is combined with interviews where first-hand clinical or purchasing insight is necessary.

Clinical needs and user research

Structured interviews test whether the proposed problem, workflow and value proposition match clinical reality. This work can reshape product requirements, positioning, evidence plans and the order of market entry.

Entry and partnership strategy

We develop a sequenced plan covering target segment, early clinical sites, strategic partners, evidence needs, messaging and the decisions required before commercial scaling.

Clinical adoption and workflow transfer

When a product is installed but not routinely used, we compare high-use and low-use settings, map the workflow and identify missing responsibilities, training, evidence or incentives. The aim is a transferable adoption model rather than dependence on a single champion.

Clinical user and advisory programmes

Scope can include:

  • clinical and scientific advisory boards;
  • key opinion leader identification and engagement;
  • recurring user groups;
  • case-based education and workflow exchange;
  • structured user feedback;
  • ethically and legally appropriate real-world evidence planning.

KOL activity is treated as part of clinical adoption and evidence, not as an isolated visibility exercise.

Relevant experience

The documented work spans German market-entry and reimbursement assessments for companies from across Europe, Israel and the United States; product and pricing strategy for medical software; DiGA pathway work; clinical partner identification; reference-site development; and international clinical user programmes.

Examples include digital therapeutics, neuroimaging, AI-assisted radiology, clinical decision support, telehealth, wearables, rehabilitation technology, laboratory platforms and medical devices.

Deliverables

A project may produce:

  • Germany or Europe market-entry assessment;
  • indication and segment prioritisation;
  • stakeholder and decision-pathway map;
  • reimbursement and DiGA pathway assessment;
  • clinician or buyer interview report;
  • reference-site strategy;
  • adoption audit and workflow model;
  • clinical advisory-board or user-programme design;
  • 90-day decision and implementation plan.

Boundaries

Quint Healthcare does not provide legal advice, reimbursement guarantees or a sales agency. Country-specific health-economic, legal and payer expertise is added where required. Market-entry recommendations state the assumptions and evidence behind them so that management can make an informed decision.

A practical starting point

Market-entry and adoption assessment

We review the product, intended purpose, current evidence, existing traction and target market. The output identifies the most credible entry pathway, the stakeholders whose decisions matter, the principal adoption risks and the evidence or partnerships required next.